gabapentin and Bilateral Headache
gabapentin has been researched along with Bilateral Headache in 39 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 9.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 9.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " Gabapentin or TCAs were prescribed to some patients during their follow-ups for headache treatment, based on physician judgment." | 7.91 | Gabapentin and Tricyclics in the Treatment of Post-Concussive Headache, a Retrospective Cohort Study. ( Borowski, L; Bushman, T; Cushman, DM; Hansen, C; Hendrick, J; Teramoto, M, 2019) |
| "Headache is the most prevalent symptom of acute mountain sickness." | 6.73 | Low-dose gabapentin in treatment of high-altitude headache. ( Gorouhi, F; Jafarian, S; Lotfi, J; Salimi, S, 2007) |
| "Gabapentin was effective for the prevention of HAH and had satisfactory tolerability." | 6.73 | Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial. ( Abolfazli, R; Gorouhi, F; Jafarian, S; Lotfi, J; Rezaie, S, 2008) |
| "Headache after aneurysmal subarachnoid hemorrhage (SAH) is very common and is often described as the "worst headache imaginable." | 5.42 | Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 5.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 5.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 5.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses." | 5.08 | High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Gabapentin (GBP) is a antiepileptic drug (AED) indicated as adjunct therapy for treatment of partial seizures, with and without secondary generalization, in patients 12 and older with epilepsy." | 4.80 | Gabapentin. ( Morris, GL, 1999) |
| " Gabapentin or TCAs were prescribed to some patients during their follow-ups for headache treatment, based on physician judgment." | 3.91 | Gabapentin and Tricyclics in the Treatment of Post-Concussive Headache, a Retrospective Cohort Study. ( Borowski, L; Bushman, T; Cushman, DM; Hansen, C; Hendrick, J; Teramoto, M, 2019) |
| "Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin." | 3.72 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| "Nummular headache is characterized by continuous or intermittent head pain, which remains circumscribed in a round or oval area of the scalp, typically one to six centimeters in diameter." | 3.01 | Epicranial headaches part 2: Nummular headache and epicrania fugax. ( Cuadrado, ML, 2023) |
| " XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily) was well absorbed (>68%, based on urinary recovery of gabapentin), converted rapidly to gabapentin, and provided dose-proportional exposure, whereas absorption of oral gabapentin declined with increasing doses to <27% at 1200 mg." | 2.73 | Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ( Canafax, DM; Cundy, KC; Luo, W; Moors, TL; Sastry, S; Zou, J, 2008) |
| "Headache is the most prevalent symptom of acute mountain sickness." | 2.73 | Low-dose gabapentin in treatment of high-altitude headache. ( Gorouhi, F; Jafarian, S; Lotfi, J; Salimi, S, 2007) |
| "Gabapentin was effective for the prevention of HAH and had satisfactory tolerability." | 2.73 | Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial. ( Abolfazli, R; Gorouhi, F; Jafarian, S; Lotfi, J; Rezaie, S, 2008) |
| " Two analyses of adverse events are presented: tolerability and safety." | 2.69 | Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999) |
| "Most of the reports of headache in GBS place it in the context of the posterior reversible encephalopathy syndrome (PRES) which is increasingly recognized as a likely dysautonomia-related GBS complication." | 2.52 | Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015) |
| "Pediatric migraine can cause a significant impact on quality of life." | 2.45 | [Antiepileptic drugs for the prevention of pediatric migraine]. ( Cuvellier, JC, 2009) |
| "Neuropathic cranial pain, i." | 2.42 | Neuropathic cranial pain. ( Annovazzi, PO; Colombo, B; Comi, G, 2003) |
| "Epicrania fugax (EF) is a primary headache consisting of brief paroxysms of pain, lasting 1-10 s, that move through different nerve territories of one hemicranium with a linear or zigzag trajectory, although there are some clinical variants." | 1.91 | Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA. ( Alberola-Amores, FJ; Moral-Rubio, J, 2023) |
| "Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks." | 1.43 | Using a graphical risk tool to examine willingness to take migraine prophylactic medications. ( Golding, AN; Houle, TT; Turner, DP, 2016) |
| "Headache after aneurysmal subarachnoid hemorrhage (SAH) is very common and is often described as the "worst headache imaginable." | 1.42 | Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus. ( Dhakal, LP; Freeman, WD; Hodge, DO; Mayes, M; Nagal, J; Nagel, J; Ng, LK; Richie, A, 2015) |
| "Treatment with gabapentin achieved complete remission." | 1.42 | Pressure pain sensitivity map of multifocal nummular headache: a case report. ( Barón, J; Carreres, A; Cuadrado, ML; Fernández-de-Las-Peñas, C; Guerrero, AL; Herrero-Velázquez, S; Madeleine, P; Rodríguez, C; Rodríguez-Valencia, E; Ruiz, M, 2015) |
| "Occipital neuralgia is an extracranial pain that may be confused with other headaches." | 1.33 | Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 1.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
Research
Studies (39)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.82) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 12 (30.77) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cuadrado, ML | 3 |
| Alberola-Amores, FJ | 1 |
| Moral-Rubio, J | 1 |
| Iturri, F | 1 |
| Valencia, L | 1 |
| Honorato, C | 1 |
| Martínez, A | 1 |
| Valero, R | 1 |
| Fàbregas, N | 1 |
| García-Iglesias, C | 1 |
| Martínez-Badillo, C | 1 |
| García-Azorín, D | 1 |
| Trigo-López, J | 1 |
| Martínez-Pías, E | 1 |
| Guerrero-Peral, ÁL | 1 |
| Weng, HY | 1 |
| Cohen, AS | 1 |
| Schankin, C | 1 |
| Goadsby, PJ | 1 |
| López-Ruiz, P | 1 |
| Guerrero, ÁL | 2 |
| Cushman, DM | 1 |
| Borowski, L | 1 |
| Hansen, C | 1 |
| Hendrick, J | 1 |
| Bushman, T | 1 |
| Teramoto, M | 1 |
| Wilhour, D | 1 |
| Ceriani, CEJ | 1 |
| Nahas, SJ | 1 |
| Mah, L | 1 |
| Hart, M | 1 |
| Iwanowski, P | 1 |
| Kozubski, W | 1 |
| Losy, J | 1 |
| Dhakal, LP | 1 |
| Hodge, DO | 1 |
| Nagel, J | 1 |
| Nagal, J | 1 |
| Mayes, M | 1 |
| Richie, A | 1 |
| Ng, LK | 1 |
| Freeman, WD | 1 |
| Rodríguez, C | 1 |
| Herrero-Velázquez, S | 1 |
| Ruiz, M | 1 |
| Barón, J | 1 |
| Carreres, A | 1 |
| Rodríguez-Valencia, E | 1 |
| Madeleine, P | 1 |
| Fernández-de-Las-Peñas, C | 1 |
| Farmakidis, C | 1 |
| Inan, S | 1 |
| Milstein, M | 1 |
| Herskovitz, S | 1 |
| Turner, DP | 1 |
| Golding, AN | 1 |
| Houle, TT | 1 |
| De Cesaris, F | 1 |
| Fanciullacci, M | 1 |
| Pietrini, U | 1 |
| Anselmi, B | 1 |
| Del Bene, E | 1 |
| Cundy, KC | 1 |
| Sastry, S | 1 |
| Luo, W | 1 |
| Zou, J | 1 |
| Moors, TL | 1 |
| Canafax, DM | 1 |
| Cuvellier, JC | 1 |
| Rossi, P | 1 |
| Tassorelli, C | 1 |
| Allena, M | 1 |
| Ferrante, E | 1 |
| Lisotto, C | 1 |
| Nappi, G | 1 |
| Chen, WH | 1 |
| Li, TH | 1 |
| Lee, LH | 1 |
| Huang, CC | 1 |
| Brodie, MJ | 2 |
| Chadwick, DW | 1 |
| Anhut, H | 1 |
| Otte, A | 1 |
| Messmer, SL | 1 |
| Maton, S | 1 |
| Sauermann, W | 1 |
| Murray, G | 1 |
| Garofalo, EA | 1 |
| Neumeier, S | 1 |
| Brinkschmidt, T | 1 |
| Jensen, U | 1 |
| Burchell, BJ | 1 |
| Colombo, B | 1 |
| Annovazzi, PO | 1 |
| Comi, G | 1 |
| França, MC | 1 |
| Costa, AL | 1 |
| Maciel, JA | 1 |
| Frediani, F | 1 |
| Mourouzis, C | 1 |
| Saranteas, T | 1 |
| Rallis, G | 1 |
| Anagnostopoulou, S | 1 |
| Tesseromatis, C | 1 |
| Wamsler, C | 1 |
| Schürmann, S | 1 |
| Dubbel, G | 1 |
| Blankenburg, M | 1 |
| Zernikow, B | 1 |
| Trucco, M | 2 |
| Mainardi, F | 1 |
| Perego, G | 1 |
| Zanchin, G | 1 |
| Jafarian, S | 2 |
| Gorouhi, F | 2 |
| Salimi, S | 1 |
| Lotfi, J | 2 |
| Abolfazli, R | 1 |
| Rezaie, S | 1 |
| Wilson, EA | 1 |
| Sills, GJ | 1 |
| Forrest, G | 1 |
| García-Albea, E | 1 |
| McLean, MJ | 1 |
| Morrell, MJ | 1 |
| Willmore, LJ | 1 |
| Privitera, MD | 1 |
| Faught, RE | 1 |
| Holmes, GL | 1 |
| Magnus-Miller, L | 1 |
| Bernstein, P | 1 |
| Rose-Legatt, A | 1 |
| Gay, CT | 1 |
| Morris, GL | 1 |
| Graff-Radford, SB | 1 |
| Fragoso, YD | 1 |
| Carrazana, EJ | 1 |
| Hurley, SC | 1 |
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nummular Headache Iberian Study on the Treatments and Outcomes in Real-World Setting[NCT05475769] | 98 participants (Anticipated) | Observational | 2022-03-01 | Recruiting | |||
| Observational Prospective Study on the Presence of Typical Migraine Features in Nummular Headache Patients: The Numamig Study[NCT04299958] | 19 participants (Actual) | Observational [Patient Registry] | 2020-04-01 | Completed | |||
| Assessment of the Efficacy of Medrol Dose Pack for Post-Concussive Headaches[NCT04685772] | 25 participants (Anticipated) | Observational [Patient Registry] | 2021-04-01 | Recruiting | |||
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
Time to Drop Out
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
Portland Neurotoxicity Scale (PNS) at V6
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
QOLIE-31 (Quality Of Life In Epilepsy) Results at V6
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
Reviews
13 reviews available for gabapentin and Bilateral Headache
| Article | Year |
|---|---|
Epicranial headaches part 2: Nummular headache and epicrania fugax.
Topics: Chronic Pain; Gabapentin; Headache; Headache Disorders; Humans; Lamotrigine | 2023 |
Narrative review of acute post-craniotomy pain. Concept and strategies for prevention and treatment of pain.
Topics: Acupuncture Analgesia; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory A | 2020 |
Secondary Nummular Headache: A New Case Series and Review of the Literature.
Topics: Gabapentin; Headache; Headache Disorders; Humans; Prospective Studies; Retrospective Studies | 2021 |
Nummular headache: an update and future prospects.
Topics: Analgesics; Botulinum Toxins, Type A; Chronic Pain; Gabapentin; Headache; Humans; Injections, Subcut | 2018 |
Nummular headache: an update and future prospects.
Topics: Analgesics; Botulinum Toxins, Type A; Chronic Pain; Gabapentin; Headache; Humans; Injections, Subcut | 2018 |
Nummular headache: an update and future prospects.
Topics: Analgesics; Botulinum Toxins, Type A; Chronic Pain; Gabapentin; Headache; Humans; Injections, Subcut | 2018 |
Nummular headache: an update and future prospects.
Topics: Analgesics; Botulinum Toxins, Type A; Chronic Pain; Gabapentin; Headache; Humans; Injections, Subcut | 2018 |
Nummular Headache.
Topics: Botulinum Toxins; Chronic Pain; Female; Gabapentin; Head; Headache; Humans; Male | 2019 |
Gabapentin withdrawal: case report in an older adult and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Depression; Female; Gabapentin; gamm | 2013 |
Headache and Pain in Guillain-Barré Syndrome.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Guillain-Barre Sy | 2015 |
[Antiepileptic drugs for the prevention of pediatric migraine].
Topics: Adolescent; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Tolerance; Fructose; G | 2009 |
Focus on therapy: hemicrania continua and new daily persistent headache.
Topics: Amines; Analgesics; Celecoxib; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fructose; Gaba | 2010 |
Neuropathic cranial pain.
Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Anticonvulsants; Antidepressive Agents, Tric | 2003 |
Anticonvulsant drugs in primary headaches prophylaxis.
Topics: Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fruct | 2004 |
Gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; | 1999 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Trials
8 trials available for gabapentin and Bilateral Headache
| Article | Year |
|---|---|
Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Anticonvulsants; Cross-Over Studies; Female; | 2018 |
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
Topics: Adult; Aged; Amines; Area Under Curve; Biological Availability; Capsules; Carbamates; Cross-Over Stu | 2008 |
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan | 2002 |
Low-dose gabapentin in treatment of high-altitude headache.
Topics: Adolescent; Adult; Altitude Sickness; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind | 2007 |
Gabapentin for prevention of hypobaric hypoxia-induced headache: randomized double-blind clinical trial.
Topics: Adolescent; Adult; Aged; Altitude Sickness; Amines; Cyclohexanecarboxylic Acids; Disorders of Excess | 2008 |
High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diarrhea; D | 1998 |
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Asthenia; Carbamazepine; Cycl | 1999 |
Low doses of gabapentin may be helpful in the management of chronic daily headache.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic | 2000 |
Other Studies
18 other studies available for gabapentin and Bilateral Headache
| Article | Year |
|---|---|
Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.
Topics: Botulinum Toxins, Type A; Gabapentin; Headache; Headache Disorders; Humans; Pain | 2023 |
Gabapentin and Tricyclics in the Treatment of Post-Concussive Headache, a Retrospective Cohort Study.
Topics: Adolescent; Adult; Analgesics; Antidepressive Agents, Tricyclic; Brain Concussion; Cohort Studies; F | 2019 |
Nummular headache in a patient with ipsilateral occipital neuralgia--a case report.
Topics: Amines; Analgesics; Anesthetics, Local; Bupivacaine; Comorbidity; Cyclohexanecarboxylic Acids; Femal | 2014 |
Safety and tolerability of gabapentin for aneurysmal subarachnoid hemorrhage (sah) headache and meningismus.
Topics: Adult; Aged; Amines; Analgesics; Aneurysm, Ruptured; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2015 |
Pressure pain sensitivity map of multifocal nummular headache: a case report.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2015 |
Using a graphical risk tool to examine willingness to take migraine prophylactic medications.
Topics: Amines; Analgesics; Antidepressive Agents; Antihypertensive Agents; Cross-Sectional Studies; Cyclohe | 2016 |
Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache center.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Autonomic Nervous System; Cyclohexanecarboxylic A | 2008 |
Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia.
Topics: 2-Aminopurine; Amines; Analgesics; Antiviral Agents; Comorbidity; Cyclohexanecarboxylic Acids; Famci | 2012 |
[Case report on a patient with SUNCT-syndrome].
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin | 2003 |
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
Topics: Acetates; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Double-Blind Method; G | 2003 |
Gabapentin-responsive idiopathic stabbing headache.
Topics: Adolescent; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2004 |
Occipital neuralgia secondary to respiratory tract infection.
Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnos | 2005 |
[Unique children -- unique headaches. Case reports of pediatric headache patients from an outpatient children's pain department].
Topics: Amines; Analgesics; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Developing Countries; Fema | 2006 |
Nummular headache: first Italian case and therapeutic proposal.
Topics: Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acids; Female; Ga | 2006 |
Nummular headache: another case treated with gabapentin.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2007 |
[Prophylactic treatment with gabapentin in chronic daily headache resistant to other drugs].
Topics: Acetates; Adult; Aged; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Resist | 1998 |
An 8-year-old girl with unilateral facial and ear pain and isolated frontal headaches.
Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Earache; Face; Female | 1999 |
SUNCT syndrome responsive to gabapentin (Neurontin).
Topics: Acetates; Amines; Analgesics; Conjunctival Diseases; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |